EP3728307A4 - COMPOSITIONS AND METHODS OF TREATMENT OF HIV / AIDS WITH IMMUNOTHERAPY - Google Patents
COMPOSITIONS AND METHODS OF TREATMENT OF HIV / AIDS WITH IMMUNOTHERAPY Download PDFInfo
- Publication number
- EP3728307A4 EP3728307A4 EP18890907.1A EP18890907A EP3728307A4 EP 3728307 A4 EP3728307 A4 EP 3728307A4 EP 18890907 A EP18890907 A EP 18890907A EP 3728307 A4 EP3728307 A4 EP 3728307A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunotherapy
- aids
- compositions
- methods
- treating hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608479P | 2017-12-20 | 2017-12-20 | |
US201862660819P | 2018-04-20 | 2018-04-20 | |
PCT/US2018/066744 WO2019126464A2 (en) | 2017-12-20 | 2018-12-20 | Compositions and methods for treating hiv/aids with immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3728307A2 EP3728307A2 (en) | 2020-10-28 |
EP3728307A4 true EP3728307A4 (en) | 2021-05-19 |
Family
ID=66993881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18890907.1A Pending EP3728307A4 (en) | 2017-12-20 | 2018-12-20 | COMPOSITIONS AND METHODS OF TREATMENT OF HIV / AIDS WITH IMMUNOTHERAPY |
Country Status (7)
Country | Link |
---|---|
US (2) | US10894819B2 (ja) |
EP (1) | EP3728307A4 (ja) |
JP (2) | JP7377802B2 (ja) |
CN (1) | CN111954677A (ja) |
AU (1) | AU2018388997A1 (ja) |
CA (1) | CA3086612A1 (ja) |
WO (1) | WO2019126464A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3086612A1 (en) * | 2017-12-20 | 2019-06-27 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
EP3807317A4 (en) * | 2018-06-15 | 2022-03-30 | The Regents of University of California | CHIMERIC FUSION FRAGMENT ANTIGEN RECEPTORS AND USES THEREOF |
KR20230042090A (ko) * | 2020-07-29 | 2023-03-27 | 내션얼 리서치 카운슬 오브 캐나다 | 항-cd22 단일 도메인 항체 및 치료학적 작제물 |
CN112341538A (zh) * | 2020-10-27 | 2021-02-09 | 苏州复融生物技术有限公司 | 一种Fc单体多肽及其应用 |
CN114539421B (zh) * | 2020-11-18 | 2024-03-12 | 复旦大学 | 以HIV-1 gp120与CD20为双靶点的CAR-T细胞制备方法及其应用 |
EP4141028A1 (en) * | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
CN114163534B (zh) * | 2021-11-08 | 2023-07-18 | 复旦大学 | 一种靶向hiv-1病毒囊膜蛋白的双特异性嵌合抗原受体及其制备方法和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130108636A1 (en) * | 2010-05-21 | 2013-05-02 | Dimiter S. Dimitrov | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
WO2015017755A1 (en) * | 2013-08-02 | 2015-02-05 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
WO2015077789A2 (en) * | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
US20160039904A1 (en) * | 2013-03-15 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Stabilized single human cd4 domains and fusion proteins |
WO2016153572A1 (en) * | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
WO2016201394A1 (en) * | 2015-06-12 | 2016-12-15 | Miltenyi Biotec Technology, Inc. | Method to treat cancer with engineered t-cells |
WO2018129524A1 (en) * | 2017-01-09 | 2018-07-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
EP0630234B1 (en) | 1992-03-12 | 1997-06-11 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
CA2359892A1 (en) * | 1999-01-08 | 2000-07-13 | Panacos Pharmaceuticals, Inc. | Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41 |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
CA2775350A1 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
WO2011106723A2 (en) | 2010-02-26 | 2011-09-01 | Lpath, Inc. | Anti-paf antibodies |
ES2680151T3 (es) * | 2012-03-01 | 2018-09-04 | Amgen Research (Munich) Gmbh | Moléculas de unión de polipéptidos de larga duración |
CA3086612A1 (en) * | 2017-12-20 | 2019-06-27 | Lentigen Technology, Inc. | Compositions and methods for treating hiv/aids with immunotherapy |
-
2018
- 2018-12-20 CA CA3086612A patent/CA3086612A1/en active Pending
- 2018-12-20 WO PCT/US2018/066744 patent/WO2019126464A2/en unknown
- 2018-12-20 CN CN201880089736.7A patent/CN111954677A/zh active Pending
- 2018-12-20 AU AU2018388997A patent/AU2018388997A1/en active Pending
- 2018-12-20 EP EP18890907.1A patent/EP3728307A4/en active Pending
- 2018-12-20 JP JP2020534253A patent/JP7377802B2/ja active Active
- 2018-12-20 US US16/228,077 patent/US10894819B2/en active Active
-
2020
- 2020-12-15 US US17/122,847 patent/US20210206839A1/en active Pending
-
2023
- 2023-10-30 JP JP2023185402A patent/JP2024016109A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130108636A1 (en) * | 2010-05-21 | 2013-05-02 | Dimiter S. Dimitrov | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins |
US20160039904A1 (en) * | 2013-03-15 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Stabilized single human cd4 domains and fusion proteins |
WO2015017755A1 (en) * | 2013-08-02 | 2015-02-05 | The Regents Of The University Of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
WO2015077789A2 (en) * | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
WO2016153572A1 (en) * | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
WO2016201394A1 (en) * | 2015-06-12 | 2016-12-15 | Miltenyi Biotec Technology, Inc. | Method to treat cancer with engineered t-cells |
WO2018129524A1 (en) * | 2017-01-09 | 2018-07-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
Non-Patent Citations (8)
Title |
---|
CHEN W. ET AL: "Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains", JOURNAL OF VIROLOGY, vol. 88, no. 2, 6 November 2013 (2013-11-06), US, pages 1125 - 1139, XP055791712, ISSN: 0022-538X, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3911630/pdf/zjv1125.pdf> DOI: 10.1128/JVI.02566-13 * |
LIU BINGFENG ET AL: "Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4 T Lymphocytes Isolated from HIV-1- Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy", JOURNAL OF VIROLOGY, vol. 90, no. 21, 17 August 2016 (2016-08-17), US, pages 9712 - 9724, XP055790583, ISSN: 0022-538X, Retrieved from the Internet <URL:https://jvi.asm.org/content/jvi/90/21/9712.full.pdf> DOI: 10.1128/JVI.00852-16 * |
LIU LI ET AL: "Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity", JOURNAL OF VIROLOGY, vol. 89, no. 13, 15 April 2015 (2015-04-15), US, pages 6685 - 6694, XP055790584, ISSN: 0022-538X, Retrieved from the Internet <URL:https://jvi.asm.org/content/jvi/89/13/6685.full.pdf> DOI: 10.1128/JVI.00474-15 * |
MALIKA HALE ET AL: "Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells", MOLECULAR THERAPY, vol. 25, no. 3, 31 March 2017 (2017-03-31), pages 570 - 579, XP055551542, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2016.12.023 * |
P. M. YOUNAN ET AL: "Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model", BLOOD, vol. 122, no. 2, 29 May 2013 (2013-05-29), US, pages 179 - 187, XP055289542, ISSN: 0006-4971, DOI: 10.1182/blood-2013-01-482224 * |
QI QIANQIAN ET AL: "HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions", EMERGING MICROBES & INFECTIONS, vol. 6, no. 1, 1 January 2017 (2017-01-01), pages 1 - 7, XP055791713, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520319/pdf/emi201746a.pdf> DOI: 10.1038/emi.2017.46 * |
SCOTT WILKIE ET AL: "Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling", JOURNAL OF CLINICAL IMMUNOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 32, no. 5, 17 April 2012 (2012-04-17), pages 1059 - 1070, XP035113362, ISSN: 1573-2592, DOI: 10.1007/S10875-012-9689-9 * |
XIAOYING CHEN ET AL: "Fusion protein linkers: Property, design and functionality", NIH PUBLIC ACCESS AUTHOR MANUSCRIPT, 1 October 2013 (2013-10-01), pages 1 - 32, XP055341428, DOI: 10.1016/j.addr.2012.09.039 * |
Also Published As
Publication number | Publication date |
---|---|
JP7377802B2 (ja) | 2023-11-10 |
US10894819B2 (en) | 2021-01-19 |
US20190202895A1 (en) | 2019-07-04 |
JP2024016109A (ja) | 2024-02-06 |
WO2019126464A2 (en) | 2019-06-27 |
CN111954677A (zh) | 2020-11-17 |
WO2019126464A3 (en) | 2019-08-08 |
JP2021506306A (ja) | 2021-02-22 |
US20210206839A1 (en) | 2021-07-08 |
CA3086612A1 (en) | 2019-06-27 |
EP3728307A2 (en) | 2020-10-28 |
AU2018388997A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3589373A4 (en) | COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY | |
EP3638289A4 (en) | PDE5 COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY | |
EP3765608A4 (en) | GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | |
EP3823673A4 (en) | ANTI-CD112R COMPOSITIONS AND METHODS | |
EP3493827A4 (en) | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | |
EP3765094A4 (en) | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY | |
EP3600325A4 (en) | UNIQUE COMPOSITIONS AND PROCESSES | |
EP3728307A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF HIV / AIDS WITH IMMUNOTHERAPY | |
EP3402495A4 (en) | METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY WITH T-LYMPHOCYTES | |
EP3286213A4 (en) | Methods and compositions for combination immunotherapy | |
EP3242940A4 (en) | Methods and compositions for combination immunotherapy | |
EP3765092A4 (en) | GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | |
EP3413926A4 (en) | HIV VACCINATION AND IMMUNOTHERAPY | |
EP3408344A4 (en) | METHOD AND COMPOSITIONS FOR BORING TREATMENT | |
EP3503879A4 (en) | COMPOSITION AND METHOD FOR IT | |
EP3704227A4 (en) | COMPOSITION AND PROCESS | |
EP3455322A4 (en) | HYDROFLUOROLEFINE AND METHOD FOR USE THEREOF | |
EP3442543A4 (en) | COMPOSITIONS AND METHODS FOR NEUROGENESIS | |
EP3436083A4 (en) | NEW COMPOSITIONS AND METHODS | |
EP3538189A4 (en) | COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES | |
EP3512524A4 (en) | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | |
EP3310783A4 (en) | Methods and compositions for the prevention and treatment of hearing loss | |
EP3635000A4 (en) | MANABODIES AND METHODS OF USE | |
EP3844500A4 (en) | RP182 COMPOSITIONS AND METHODS | |
EP3317290A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200717 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210416 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/725 20060101AFI20210412BHEP Ipc: C07K 14/155 20060101ALI20210412BHEP Ipc: A61K 35/17 20150101ALI20210412BHEP Ipc: C12N 5/0783 20100101ALI20210412BHEP Ipc: A61P 31/18 20060101ALI20210412BHEP Ipc: A61K 38/00 20060101ALI20210412BHEP Ipc: A61K 39/00 20060101ALI20210412BHEP Ipc: A61P 35/00 20060101ALI20210412BHEP Ipc: C07K 16/10 20060101ALI20210412BHEP Ipc: A61K 39/21 20060101ALI20210412BHEP Ipc: C07K 14/16 20060101ALI20210412BHEP |